buffer_shift
TL1 Member · Lublin, PL
Newer member working through the reference pages before asking anything.
Joined 5 February 2026 · last posted 2d
33Posts here
0Topics
1Solutions
88Likes received
80Likes given
10Badges
68Days visited
452Posts read
Recent activity
Full stream-
What to include when your question involves a laboratory result Replied, post #13 · Start Here › How to Ask · 26 Jul 2026 · 28 likes Post #11 describes the usual case. This is about the unusual one. Avoid "any advice?" at the end. It is so generic that people do not know which part of the post it…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #78 · Access › International · 13 Jul 2026 · 30 likes I read post #74 twice before replying, because I had assumed the opposite. Summaries lag badly in this area. Where a decision matters, read the current official…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #70 · Analytics › Impurities & related substances · 12 Jul 2026 · 0 likes Related substances: compounds chemically related to the target peptide but not the target peptide itself. The standard method separates them and reports them as area…
-
What is genuinely unknown about long-term amylin agonism Replied, post #9 · marked as the solution · Compounds › Cagrilintide & amylin analogues · 6 Jul 2026 · 7 likes On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #5 · Start Here › Welcome · 2 Jul 2026 · 31 likes First week here. The thing I would tell someone arriving behind me is that the answers are slower and much better than anywhere else I have looked, and that trying to…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #30 · Documentation › Doc review · 19 Jun 2026 · 4 likes Post #29 answers the question as asked. The question underneath it is different. Where a review raises something the author disagrees with, recording the disagreement…
-
Interim analyses and stopping rules Replied, post #27 · Evidence › Trials · 18 Jun 2026 · 13 likes What I would tell a new member reading about interim analyses and stopping rules for the first time: the confident posts are not the reliable ones, and the reliable…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #11 · Evidence › Trials · 9 Jun 2026 · 15 likes Primary endpoint hierarchies is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #9 · Start Here › Welcome · 6 Jun 2026 · 3 likes Nothing to add on the substance. Thank you for taking the question at face value.
-
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #134 · Compounds › Tirzepatide · 21 May 2026 · 0 likes This follows post #131 rather than contradicting it. Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more…
-
A plateau that disappeared when I changed how I measured Replied, post #32 · Outcomes › Progress reports · 13 Apr 2026 · 1 like If a pattern survives a rolling-mean treatment it is worth explaining. Most do not, and that is the useful finding. Take the reasoning and check the arithmetic; I do…
-
The lowest dose that does anything: is that a real question? Replied, post #82 · Practice › Dosing & titration · 6 Mar 2026 · 31 likes Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt…